Company / Operating Income
Nurix Therapeutics, Inc. Operating Income History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$285.7M
FY2025
5-year range
-$285.7M / -$22.2M
FY2021-FY2025
Trend
-34.1%
vs FY2024
Sector context
#162 of 204
Health Care
What the data says
Nurix Therapeutics, Inc.'s operating income of -$286M is lower than 79% of companies in the Health Care sector (FY2025). Operating Income has declined for 4 consecutive years, from -$22M in FY2021 to -$286M in FY2025.
Based on SEC 10-K filings.
-$286M in FY2025.
Declined from -$155M to -$286M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 21% in Health CareTop 79% of 204This company -$285.7M Sector average $107.8M
▼
-365.1% below sector average
Key checks
Key Insights
- Nurix Therapeutics, Inc.'s operating income has declined for 4 consecutive years.
- In FY2025, operating income decreased 34.1% year-over-year.
- Ranks #162 out of 204 companies in the Health Care sector.
- Peak operating income was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score -0.35 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$285.7M | -34.1% |
| FY2024 | -$213.0M | -37.4% |
| FY2023 | -$155.1M | -31.5% |
| FY2022 | -$117.9M | -430.2% |
| FY2021 | -$22.2M | +65.8% |
| FY2020 | -$65.0M | -192.2% |
| FY2019 | -$22.2M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026